Welcome to our dedicated page for Minerva Neurosci SEC filings (Ticker: NERV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Minerva Neurosciences, Inc. (Nasdaq: NERV) SEC filings page on Stock Titan consolidates the company’s regulatory documents from EDGAR with AI-powered summaries to help readers interpret complex disclosures. As a clinical-stage biopharmaceutical company focused on central nervous system (CNS) diseases, Minerva uses its SEC reports to describe the status of its lead drug candidate roluperidone for negative symptoms of schizophrenia, its MIN-301 program for Parkinson’s disease, and the financial resources supporting these efforts.
In annual reports on Form 10-K and quarterly reports on Form 10-Q, Minerva provides audited and interim financial statements, research and development and general and administrative expense details, information about its liability related to the sale of future royalties, and discussion of risks associated with clinical development and regulatory review. These filings also reference the Complete Response Letter issued by the U.S. Food and Drug Administration (FDA) for the roluperidone New Drug Application and the requirement for a confirmatory Phase 3 trial.
Current reports on Form 8-K capture material events such as the October 2025 securities purchase agreement for Series A Convertible Preferred Stock and warrants, the related private placement financing of up to $200 million in gross proceeds, and the appointment of new directors and consulting arrangements tied to roluperidone’s Phase 3 program. Definitive proxy statements on Schedule 14A outline proposals for stockholder votes, including increases in authorized common stock, approval of common shares issuable upon conversion of the Series A Preferred Stock, and amendments to the company’s equity incentive plan.
On Stock Titan, each 10-K, 10-Q, 8-K, DEF 14A and related document is accompanied by AI-generated highlights that explain key points in plain language, such as how Minerva plans to use proceeds from financings, how it describes the design of its confirmatory trial, and what changes are proposed to its capital structure. Real-time updates from EDGAR and easy access to insider- and governance-related disclosures allow users to review Minerva’s regulatory history and understand how clinical, financial and corporate decisions are documented over time.
Registration covers up to $200,000,000 of securities. Minerva Neurosciences is registering an at‑the‑market shelf to offer, from time to time, up to $200,000,000 of common stock, preferred stock, debt securities and warrants, alone or in combination. The prospectus is a shelf framework; specific terms and proceeds will be set in prospectus supplements.
The filing discloses clinical plans for the lead candidate, roluperidone: a Phase 3 C19 trial expected to start in Q2 2026 enrolling 380 patients with topline efficacy in 2H 2027 and relapse data in 2H 2028. As of February 28, 2026, 43,274,398 shares of common stock were outstanding.
Minerva Neurosciences reports 2025 results and details next steps for its lead drug, roluperidone, after receiving an FDA Complete Response Letter in February 2024. The company is a clinical‑stage CNS biopharmaceutical developer focused on negative symptoms of schizophrenia.
Minerva plans a new 380‑patient Phase 3 confirmatory trial (C19) of once‑daily 64 mg roluperidone versus placebo, with first patient screening expected in the second quarter of 2026, a 12‑week primary endpoint on the PANSS Marder negative symptoms factor score, and a 40‑week relapse‑assessment phase. Topline efficacy data are expected in the second half of 2027 and relapse data in the second half of 2028.
The company recorded a 2025 net loss of $293.4 million, compared with net income of $1.4 million in 2024, and had an accumulated deficit of $688.8 million as of December 31, 2025. Minerva highlights extensive business risks, including continued losses, reliance on additional capital, and dependence on roluperidone’s clinical and regulatory success.
Minerva Neurosciences reported a large GAAP net loss of
On a non-GAAP basis, adjusted net loss for 2025 was
That financing delivered
Minerva Neurosciences discloses a 9.99% beneficial ownership position by Coastlands entities. The reporting persons state ownership of 4,563,031 shares, based on 43,274,398 shares outstanding as of
The filing clarifies shared voting and dispositive power of 4,563,031 shares across Coastlands Capital LP, related entities, and Matthew D. Perry, and disclaims group membership and additional beneficial ownership beyond the 9.99% limitation.
Minerva Neurosciences, Inc. received a Schedule 13G from Logos Global Management and related entities reporting significant passive ownership of its common stock. Logos Global and several affiliated funds and managers together report beneficial ownership positions up to 4,435,444 shares, or 9.9% of Minerva’s common stock.
The holdings include a mix of common shares and Tranche A warrants for Series A preferred stock that is convertible into additional common shares, subject to a 9.99% voting securities cap that limits conversions above that level. The filing states the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control. Ownership percentages are calculated against 43,274,398 common shares outstanding as of December 23, 2025.
Balyasny Asset Management and affiliated entities report a 4,330,315-share beneficial stake in Minerva Neurosciences, Inc., equal to approximately 9.99% of the common stock. The position is held through Atlas Private Holdings (Cayman) Ltd., for which Balyasny serves as investment manager.
The ownership calculation is based on 43,274,398 Minerva shares outstanding as of December 23, 2025. The reported amount includes 4,265,402 shares and 64,913 additional shares issuable upon exercise of 13,500 warrants, which are subject to a 9.99% Beneficial Ownership Limitation blocker.
The filing states the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Minerva Neurosciences. All reporting persons indicate sole voting and dispositive power over the reported shares and no shared power.
Adage Capital Management and affiliates reported a 6.35% beneficial stake in Minerva Neurosciences common stock. The group is deemed to beneficially own 2,838,000 shares of common stock, based on 43,274,398 shares outstanding as of December 23, 2025.
This amount includes 1,419,000 shares issuable upon conversion of preferred stock underlying warrants held by Adage Capital Partners. All voting and dispositive powers are shared among Adage Capital Management, Robert Atchinson, and Phillip Gross, and the securities are described as acquired and held in the ordinary course of business, not for the purpose of influencing control.
Minerva Neurosciences, Inc. received an updated ownership report from Farallon-managed funds. The Farallon Funds together hold 2,365,000 common shares of Minerva and 5,000 Tranche A warrants, each warrant exercisable into one share of Series A convertible voting preferred stock.
Each Series A preferred share is convertible into 473 common shares, subject to a 9.99% Beneficial Ownership Limitation, which currently allows conversion into up to 2,174,854 common shares. Farallon Partners, L.L.C. reports beneficial ownership of 4,316,598 shares, or 9.5% of the common stock. Several Farallon individual reporting persons, including Joshua J. Dapice and others, each report beneficial ownership of 4,539,854 shares, or 9.99% of the class.
The amendment also notes that effective January 1, 2026, Avner A. Husen became a member or manager of the Farallon general partner entities, while effective December 31, 2025, Richard B. Fried, Rajiv A. Patel and William Seybold ceased those roles. The reporting group certifies the holdings are not for the purpose of changing or influencing control of Minerva.
Minerva Neurosciences is preparing a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, discussed at a virtual key opinion leader event. A supporting presentation is being made available on the company’s investor relations website.
The Phase 3 trial is expected to begin, including first patient screened, in the second quarter of 2026 and enroll 380 patients randomized 1:1 to placebo or a daily 64 mg dose of roluperidone. The primary goal is change from baseline at 12 weeks on the PANSS Marder negative symptoms factor score.
After 12 weeks, patients are expected to enter a 40‑week relapse assessment phase, receiving either roluperidone or antipsychotics. The company currently expects topline efficacy results in the second half of 2027 and relapse assessment data in the second half of 2028, while highlighting numerous clinical, financial, and regulatory risks to these plans.